Heartbeam Inc Stock Price, News & Analysis

HeartBeam, Inc. (NASDAQ: BEAT) announced the issuance of a patent for its AIMIGo™ device, which provides 12-lead ECG capability, enhancing heart attack detection. This patent, granted by the European Patent Office, covers several European countries, validating HeartBeam's innovative technology. With over 11 million new cardiovascular disease cases annually in Europe, the AIMIGo device aims to allow patients to monitor their heart health outside medical settings. The innovation supports timely diagnosis and intervention for cardiac patients.

HeartBeam, Inc. (NASDAQ: BEAT) has announced significant advancements in their cardiac technology products, particularly the HeartBeam AIMIGo and HeartBeam AIMI systems, aimed at enhancing heart attack detection. The company anticipates regulatory approval for the HeartBeam AIMI system in Q1 2023 and plans to submit HeartBeam AIMIGo for FDA clearance soon. HeartBeam aims to transform patient care by providing remote heart attack detection with their innovative 12-lead 3D vector ECG technology. They have also strengthened their intellectual property with several new patents, positioning themselves for growth in the healthcare market.

HeartBeam, Inc. (NASDAQ: BEAT) has partnered with Evolve Manufacturing Technologies to manufacture the AIMIGo 3D vector electrocardiogram (VECG) device. This credit card-sized device facilitates remote heart attack detection and is expected to enter early market testing in Q2 2023, pending FDA clearance. The AIMIGo solution aims to enhance heart attack detection for patients outside medical settings, addressing a significant need as more than 18 million U.S. citizens suffer from coronary artery disease.

HeartBeam, Inc. (NASDAQ: BEAT) has received an allowed patent for a 12-lead ECG smartwatch designed to detect heart attacks and complex cardiac arrhythmias, according to a recent announcement. This innovative technology aims to disrupt the multi-billion dollar wearable device market, which is projected to reach $196B by 2030. HeartBeam's platform enables diagnostic capabilities outside traditional medical settings, positioning the company favorably in a rapidly expanding market.

HeartBeam, Inc. (NASDAQ: BEAT) announced the submission of its HeartBeam AIMI™ platform for FDA clearance, enhancing its heart attack detection technology. The company also plans to submit the AIMIGo telehealth solution by Q4 2022. With two new patents granted, HeartBeam aims to expand its product pipeline to include smartwatch connectivity. Financially, the company reported a net loss of $3.6 million for Q3 2022, up from $1.2 million the previous year, with research and development expenses reaching $1.6 million. Cash reserves stood at $6.5 million as of September 30, 2022.

HeartBeam, Inc. (NASDAQ: BEAT), a leader in cardiac technology, will hold a conference call on November 10, 2022, at 4:30 p.m. Eastern time to discuss its Q3 results for the period ending September 30, 2022. CEO Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will lead the call, reviewing recent announcements and future milestones. A press release detailing results will precede the call. Investors can access the call via dial-in or webcast, and a replay will be available until February 10, 2023.

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology firm, will present at the LD Micro Main Event XV Conference in Los Angeles from October 25-27, 2022. CEO Branislav Vajdic, PhD, will lead in-person meetings and a presentation on October 25 at 4:30 pm PT in TRACK 3. The conference highlights HeartBeam's unique 3D-vector ECG technology for heart attack detection. The presentation can be streamed live or viewed later on their investor relations site. More details on registration and the conference can be found online.

HeartBeam, Inc. (NASDAQ: BEAT) announced the appointment of Dr. Peter J. Fitzgerald as Chief Medical Officer. Dr. Fitzgerald, a leader in interventional cardiology, brings extensive clinical experience and expertise in developing industry collaborations. He aims to enhance clinical strategies and partnerships for advancing HeartBeam's novel diagnostic tools, including the 3D-vector ECG platform designed for heart attack detection. HeartBeam's innovative products, AIMI™ and AIMIGo™, are currently pending FDA clearance, with potential to significantly improve patient outcomes.

HeartBeam, Inc. (NASDAQ: BEAT) has announced the expansion of its product portfolio to address the multibillion-dollar atrial arrhythmia detection market. New developments include the HeartBeam AIMIGo™ 3L device, designed to record 3D cardiac activity and facilitate clinician reviews with a planned FDA submission in Q4 2022. Future versions will add smartwatch connectivity and enhanced atrial fibrillation detection. The company is also ensuring component procurement for device production to mitigate supply chain issues, pushing towards comprehensive cardiac care anytime, anywhere.